- Ever get
Find out about participating in a Cluster Headache research study from home!
- Explore options for
moderate to severe acne
A research study on severe acne is available — learn more about participating from home.
- Know someone
living with NASH?
Learn more about participating in a NASH research study from the comfort of your own home!
If you're kind, useful and awesome, join us at Science 37!
Watch our videos
A patient's story, what Science 37 cares about, and other interesting stories...
What is NORA®?
Patient Centered Design
Watch Our Videos
We Are Better Together
Clinical research is about collaboration and togetherness to help improve the lives of patients across all cultural backgrounds. We are proud of our diverse company and our mission to accelerate biomedical research by putting patients first.
The Gift of Hope
A patient's journey with a rare disease tells the story of participating in a Science 37-enabled clinical research trial. The hope for a better future and a rewarding experience of contributing to scientific knowledge are among the benefits.
When you first heard about Science 37, this was probably the second or third question in your mind. Have a peek and hear about some brilliant reasons explained by our employees.
Taking the Lead to Build Awareness
Our very own influencer is hitting the pavement to help build awareness about clinical research. Have a look and you'll see that we have our work cut out for us. We're taking the lead and we're on it!
Awesome People on a Shared Mission
Science 37's mission is to accelerate biomedical research by putting patients first. We value being kind, useful, and awesome. We always keep our quality high. Through our strong value of company culture, we hope to create the most fulfilling jobs for our employees which translates to the best service for our patients and customers.
What is NORA®
NORA® stands for Network Oriented Research Assistant, and is the 21 CFR Part 11 compliant technology platform that allows Science 37 to bring research directly to patients in their own homes. NORA® integrates telemedicine technology into the clinical research process, and supports Science 37’s end-to-end management of clinical trials. From the first steps of trial design, to connecting with patients at home, NORA® is there to help. Contact us to learn more.
Impact of the Science 37 Approach
Metasite™-enabled clinical trials remove geographic barriers and unlock access to patients no matter where they live. These site-less trials eliminate the barriers of traditional sites that include inaccessibility due to geography and the inconvenience posed by site visits. Our dedicated research staff are highly engaged with participants which builds trust and improves the patient’s experience. Metasites increase the speed of trials by designing study activities around the lives of patients.
You may be eligible to take part in a Science 37 trial. Learn more about how to participate.Read More
Learn how to accelerate your clinical trial.
Science 37 offers end-to-end clinical trial services from protocol design and regulatory strategy to recruitment strategies and remote execution. Experience a truly connected clinical trial research process, from digitally enabled data collection, transfer, analysis and storage to trials by design that connect and recruit patients no matter where they live. Work with us to accelerate discovery and improve patient health.
You can help your patients learn more about clinical research opportunities. You can stay connected to your patients while they participate in a trial. Find out how.Read More
Meet Our Virtual Trial Specialists
- Trial Team (45)
- Physician Experts (38)
- Technology Team (25)
- Administrative Team (15)
- Leadership Team (15)
- Board of Directors (7)
- Advisors (5)
- All (138)
Science 37 Raises $29M To Bring Clinical Trials Directly Into Patients’ HomesScience 37, a trailblazing company focused on “site-less” clinical trials, announced today $29 million in Series C funding led by Glynn Capital Management with participation from GV. The round included new strategic investments from Amgen Ventures, as well as participation from all existing investors Lux Capital, Redmile Group, dRx Capital (a Qualcomm and Novartis joint…
Science 37 and Sanofi Introduce a New PartnershipWithout clinical trials, new medicine may never make it from the research lab to patients in need. These carefully designed studies can provide important data that include proper dosage, benefit to patients, and potential side effects. There is a growing challenge, however, in finding appropriate participants, especially for treatments that target highly specific conditions affecting narrower patient populations. Right now, there are more than 40,000 clinical studies recruiting patients in the U.S. alone, with some…
An Exciting VC/CEO Discussion at WinterTechHealth 2.0 Conferences are the leading showcase of cutting-edge innovation that's transforming health and health care. They present the best minds, technologies and resources in compelling panels, discussions, and live product demonstrations worldwide.
Playing for the Long Term – NYT DealBook Conference(Science Launch with Dr. Noah Craft Co-founder and CEO of Science 37 - courtesy of New York Times DealBook Conference) Two weeks ago, I was presented with a great opportunity to speak amongst some very distinguished individuals at the New York Times DealBook Conference. In a modern world of instant gratification, this conference gave some innovators the chance to come together and speak of long term visions or goals. With Science 37, we're combining technology advances that have…
Science 37 Secures $31M Series B Funding to Expand Clinical Trial Access to Anyone, Anywhere, AnytimeLOS ANGELES, Oct. 18, 2016 /PRNewswire/ -- Science 37 (http://www.science37.com), a technology-enabled clinical research company, today announced that it has completed a $31 million Series B financing. Science 37 is reimagining clinical research by bringing clinical trials to people's homes, which unlocks access to those beyond a geographical barrier. The investment will help the company grow operations, further develop its novel technology platform and continue to expand into new therapeutic areas. The Series B financing was…
What a difference a year makes!I’m just back from DPharm 2016 in Boston, where I had the pleasure of kicking off this year’s DPharm Idol competition. DPharm Idol is where a select group of companies present what they believe to be a disruptive service or technology to the traditional clinical trial process. As last year's DPharm Idol “Disruptive Innovator of the Year,” I was given the honor of presenting this year’s companies and providing an update on what Science 37…
Science 37 and AOBiome Launch Virtual PhIIb trial of Microbiome Acne TreatmentLeading skin microbiome company AOBiome announced today the launch of its Phase 2B trial using its first-in-class live bacteria to treat acne. Phase 2B marks the advancement from the company's successful Phase 1B/2A dose-ranging safety study, which resulted in no serious adverse events and no difference in adverse events between treatment and vehicle groups. The Phase 2B trial is being jointly conducted with Science 37, a clinical research organization applying breakthrough telemedicine-based approach to bring…
The White House and Stanford Medicine X Invite Science 37 to Workshop Clinical TrialsThere’s no denying that it’s a new era in medicine. Stakeholders across the healthcare system are shifting business models to focus on value. Entities that were once competitors are now working together to open data and share resources. And patients, previously siloed from their own health care decision making, are becoming true partners in care. But with all of the promise also come challenges. The evolution of research, technology and policies will take time. And…
Ready. Set. Acne!Zit, pimple, blemish, overly large red spot right in the middle of your face before a big event, these are all different ways we describe the same nemesis….acne! From those pre-pubescent days to sometimes into adulthood, we’ve all experienced waking up to acne. But do you know how they even come to be? What exactly does your body go through to produce one of these sprouting marks of annoyance? Our skin is covered in little…
Science 37 Named Clinical Informatics News Best Practices Award WinnerAt the heart of faster cures and better treatments is clinical research. It is the process through which new drugs, medical devices and biologics are brought to market. It is the way in which we advance medicine to deliver improvements in care and hope for a healthier tomorrow.
Science 37 Named in Top 40 Healthcare Transformers ListThere is no denying that technology has transformed nearly every aspect of our daily lives – from how we communicate, to the way we travel, to the process through which we make decisions. Indeed, even regulated industries, typically slow to move and resistant to change, have begun to embrace disruption
Science 37 Secures $6.5M Series A Funding To Accelerate Clinical Trial ResearchScience 37 (http://science37.com), a technology-enabled clinical research company, today announced the completion of a $6.5 million Series A financing co-led by Lux Capital and dRx Capital. The investment will accelerate Science 37’s development and rollout of its new operating model, which solves some of the greatest inefficiencies in conducting clinical trials.
Science 37 Named Disruptive Innovator of the Year at DPharm 2015
Science 37 and Precision MedicineScience 37 CEO and Co-Founder Noah Craft, MD, PhD submitted the following comments on the White House website's Precision Medicine Initiative Page.
Science 37 wins Clinical Trial Innovation PrizeIn honor of World Cancer Day 2015, the Bonnie J. Addario Lung Cancer Foundation and Free To Breathe, with support from Celgene and Genentech, created the Clinical Trial Innovation Prize. The ultimate goal of the challenge is to produce a breakthrough that doubles the accrual rate of lung cancer clinical trials. We couldn’t be happier to have been selected as one of 12 finalists and awarded one of the first three prizes in “Ideation” phase of the program.
Science 37 and LA BioMed launch telemedicine substudy arm of global PEMPHIX trialLA BioMed and Science 37 have launched their first collaborative clinical research trial and enrolled patients in the first-ever virtual, networked clinical trial using telemedicine to monitor the effects of an infusion medication. The research study will compare the effects of rituximab with another medication called mycophenolate mofetil in treating adults with active pemphigus vulgaris (PV). Pemphigus vulgaris is an auto-immune skin condition that causes your skin to form blisters. LA Biomed is one of more than 60 sites for the PEMPHIX clinical trial, sponsored by Genentech, and the only telemedicine-based site.